Trial reportMultiple sclerosis (Houndmills, Basingstoke, England)2014
Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening.
Trial report in Multiple sclerosis (Houndmills, Basingstoke, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Natalizumab for multiple sclerosis.The Cochrane database of systematic reviews · 2025Pooled it
- Trial
- Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE.Multiple sclerosis (Houndmills, Basingstoke, England) · 2018Trial
- Family history of multiple sclerosis and long-term outcomes.Journal of neurology · 2026Article
- Migration status, country of origin and long-term outcomes in multiple sclerosis: a Swedish nationwide study.Journal of neurology, neurosurgery, and psychiatry · 2026Article
- The effect of multiple sclerosis on functional status and sexual quality of life in female patients with multiple sclerosis.BMC neurology · 2026Article
- Education, Lifestyle Risk Factors, and Treatment Choices and Multiple Sclerosis Progression.JAMA network open · 2025Article
- Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials.Neurology · 2025Article
- Quality of life is decreased in persons with relapsing-remitting multiple sclerosis experiencing progression independent of relapse activity.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Observational
- Smoking and Obesity Interact to Adversely Affect Disease Progression and Cognitive Performance in Multiple Sclerosis.European journal of neurology · 2025Article
- Lifestyle changes and patient-reported outcomes over five years in a sample of people with multiple sclerosis after a single multimodal intensive lifestyle education workshop.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Obesity Affects Disease Activity and Progression, Cognitive Functioning, and Quality of Life in People With Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.Journal of patient-reported outcomes · 2024Article
- Association Between Alcohol Consumption and Disability Accumulation in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Effects of a Digital Care Pathway for Multiple Sclerosis: Observational Study.JMIR human factors · 2024Observational
- Association between sun exposure habits and disease progression in multiple sclerosis.European journal of neurology · 2024Article
- Article
- Shared Decision-Making in the Treatment of Multiple Sclerosis: Results of a Cross-Sectional, Real-World Survey in Europe and the United States.Patient preference and adherence · 2024Article
- Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.Neurology and therapy · 2023Article
- Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression.Journal of neurology, neurosurgery, and psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 29-item Multiple Sclerosis Impact Scale (MSIS-29) was developed to examine the impact of multiple sclerosis (MS) on physical and psychological functioning from a patient's perspective.
objectiveTo determine the responder definition (RD) of the MSIS-29 physical impact subscale (PHYS) in a group of patients with relapsing-remitting MS (RRMS) participating in a clinical trial.
methodsData from the SELECT trial comparing daclizumab high-yield process with placebo in patients with RRMS were used. Physical function was evaluated in SELECT using three patient-reported outcomes measures and the Expanded Disability Status Scale (EDSS). Anchor- and distribution-based methods were used to identify an RD for the MSIS-29.
resultsResults across the anchor-based approach suggested MSIS-29 PHYS RD values of 6.91 (mean), 7.14 (median) and 7.50 (mode). Distribution-based RD estimates ranged from 6.24 to 10.40. An RD of 7.50 was selected as the most appropriate threshold for physical worsening based on corresponding changes in the EDSS (primary anchor of interest).
conclusionThese findings indicate that a ≥7.50 point worsening on the MSIS-29 PHYS is a reasonable and practical threshold for identifying patients with RRMS who have experienced a clinically significant change in the physical impact of MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.